Skip to content

Press Release

Press Release

Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics

Software for analysis and reporting of single cell data will advance research into cell function, disease progression, and therapeutic response

SAN DIEGO & ASHLAND, Ore.--(BUSINESS WIRE)--Aug. 10, 2016-- Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina’s Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.

This Smart News Release features multimedia. View the full release here:

“We are excited to partner with Illumina on this project to bring new tools for analyzing and visualizing NGS data to cell biology,” said Michael Stadnisky, PhD, CEO of FlowJo, LLC. “The new offering will enhance the power of single cell biology research by empowering robust exploration of data from Illumina next-generation sequencing runs.”

“FlowJo, LLC is recognized for delivering reliable, high-quality and easy-to-use software solutions that allow cell biologists to study phenotype in individual cells by flow cytometry,” said Rob Brainin, Vice President and General Manager, Applied Genomics at Illumina. “We look forward to enabling our customers to bring these trusted FlowJo analytical capabilities to their next-generation sequencing data.”

The software will complement the end-to-end commercial solution for high-throughput sequencing of single cells that Illumina announced it is co-developing in partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb).

The companies expect the software to be available in Q1 2017.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and follow @illumina.

About FlowJo, LLC

FlowJo, LLC is a privately owned life sciences software company in Ashland, Oregon. Based on technology developed at Stanford, the company was founded in 1997 and provides the leading analysis platform for single cell flow and mass cytometry analysis. Their software innovations enable collaboration, discovery, high-throughput analysis, and data leadership in flow and mass cytometry. For more information, see

Illumina Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina assumes no obligation to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Rebecca Chambers
Gwen Gordon
FlowJo, LLC
Caitlin Farquhar